‘Techno-Optimism’ is Not Something You Should Believe In
By Jag Bhalla & Nathan J. Robinson,
Current Affairs
| 10. 20. 2023
Henk Caspers/Naturalis Biodiversity Center, CC 3.0
Techno-optimism is a dangerous philosophy whose adherents espouse the blind faith that market capitalism and technology will solve the world’s problems. In reality, this kind of optimism simply justifies elite power and promotes indifference to human suffering.
Billionaire tech investor Marc Andreessen recently published a manifesto for “techno-optimism,” a worldview that contends technology will solve all of humanity’s problems and create a world of infinite abundance for all. Andreessen’s manifesto is so extreme that it has been heavily criticized even in the tech sector. It accuses anyone who opposes the unrestricted development of AI of having blood on their hands (since AI will save lives, meaning that if you slow down its development, you are essentially a murderer). It quotes favorably from Italian fascist Filippo Tommaso Marinetti in envisioning a race of technologically-augmented “supermen” and “conquerors.” It condemns “socialism” in favor of “merit and achievement” and treats “social responsibility,” “trust and safety,” “risk management,” and even “sustainable development goals” as “enemy” ideas.
Andreessen’s manifesto comes across as unhinged and manic. It is, in fact...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...